Eurofins Scientific Shares Rise in Late Afternoon Boosted by Well-Received 2025 Results
On Friday afternoon, Eurofins Scientific shares are up 2.6% at 67.90 euros. The stock of the European leader in laboratory testing is on a favorable trend following the release of preliminary 2025 results on Thursday that exceeded expectations. Over the past year, the group's stock market performance has been distinctly positive, with a gain of 37.4%.
Solid Preliminary Results for 2025
Eurofins Scientific revealed on Thursday unaudited preliminary accounts for 2025 that demonstrate strong operational performance. Earnings per share increased by 24% to 2.31 euros, while organic growth reached 4.1% for the year. This momentum reflects the group's ability to create value in an environment where demand for analysis services remains high.
Management also confirmed their confidence in the company's trajectory by increasing the dividend proposed to shareholders by 20%, now set at 0.72 euros per share. This decision comes as the stock is currently trading 15% below its technical resistance level identified at 73.12 euros, but well above its support at 58.30 euros. The three-month trajectory shows a rebound of 11.52%, indicating renewed investor interest in this scientific services sector stock.
Significant Reassessment of Prospects by Analysts
Eurofins Scientific's case benefits from a significant reassessment of prospects by several research firms. Kepler Cheuvreux made a significant adjustment to its target on January 13, raising it from 72 to 81 euros, suggesting a potential appreciation of nearly 20% from the current price. This revision occurs in a context where the group's fundamentals seem validated by the latest financial publications.
More cautiously, Morgan Stanley also adjusted its price target at the beginning of January, raising it from 61 to 64 euros, while maintaining a market-weight recommendation on the stock. Although this target remains below the current price, it nevertheless reflects a constructive revision of estimates. These analyst movements illustrate a gradual recognition of the laboratory's operational turnaround and its ability to deploy a sustainable growth strategy across its various business segments.
